A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest independent research center focused on multiple sclerosis, has published groundbreaking new research ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

"Our findings prompt the inevitable question of whether the current phenotype classification of relapse-onset MS into relapsing-remitting and secondary progressive MS is as useful as we thought, for ...

Three investigators and their teams have received funding for clinical trial development projects as part of the International Progressive MS Alliance’s Experimental Medicine Trial Awards. These ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.